Navigation Links
Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Date:10/23/2007

CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinical trial using intravenous administration of REOLYSIN(R) in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers. The Principal Investigators are Dr. James Spicer of King's College in London, Dr. Johann de Bono and Dr. Kevin Harrington of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, and Professor Hardev Pandha of the Royal Surrey County Hospital NHS Trust, Surrey and Mount Alvernia Hospitals.

The Company also intends to host a conference call Wednesday, October 24, 2007 to provide an update on its expanding clinical program. The dial-in details appear below.

"We are really looking forward to treating patients in this trial," said Principal Investigator Dr. James Spicer. "The hope is that it will provide valuable information about the relationship between oncolytic viral therapy and the immune response of the patient."

The trial (REO 012) is an open-label, dose-escalating, non-randomized trial of REOLYSIN(R) given intravenously with escalating doses of cyclophosphamide. A standard dose of REOLYSIN(R) is administered intravenously over five consecutive days, while an intravenous dose of cyclophosphamide is administered three days before REOLYSIN(R) treatment and continues through the course of the treatment cycle. The total number of patients studied will depend on the number of dose levels tested, but it is anticipated to be approximately 30 patients.

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including pancreatic, lung and ovarian cancers that are refractory (have not responded) to stan
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... , INDIANAPOLIS , ... and manufacturing companies continued to expand in 2009, despite challenges ... in the economy, the prospect of healthcare reform and other ... announced, and service line extensions were added by companies such ...
... , New kinase array designed for ... VANCOUVER , Feb. 10 /PRNewswire/ - ... novel Protein Kinase Microarray with 200 recombinant human protein ... applications for drug target counter screening, to identify novel ...
... ... users to search the most sought after jobs in the industry anytime, anywhere. ... (PRWEB) -- MedReps.com gives members ... on the web. But in a competitive market like medical sales, job seekers need every ...
Cached Biology Technology:Indiana Biopharmaceutical Service Providers Maintain Steady Growth Despite Industry Challenges 2Indiana Biopharmaceutical Service Providers Maintain Steady Growth Despite Industry Challenges 3Indiana Biopharmaceutical Service Providers Maintain Steady Growth Despite Industry Challenges 4Kinexus Announces the Launch of a New Protein Kinase Microarray 2With the MedReps.com iPhone App, the Medical Sales Job Search Goes Mobile 2
(Date:4/16/2014)... Our ability to store memories improves during childhood, ... its connections with prefrontal and parietal cortices. New ... brain regions develop at this crucial time. Eventually, ... emerge in the transition into and during adolescence ... , Located deep in the middle of the ...
(Date:4/16/2014)... group composed of Dr. Martin Prechtl, Leo Heim and ... Chemistry has discovered a new method of generating hydrogen ... liquids is of particular interest when it comes to ... "Selective and mild hydrogen production using water and formaldehyde", ... Communications . , Among other applications, the new approach ...
(Date:4/15/2014)... community is creating a tropical home away from home ... the attention of scientists. David W. Taylor (University of ... a close look at the fresh crops in the ... gives new meaning to a phrase that food lovers ... kitchen. , "Culinary preferences tell us a good deal ...
Breaking Biology News(10 mins):How kids' brain structures grow as memory develops 2The human food connection: A new study reveals more about our relationship to food 2The human food connection: A new study reveals more about our relationship to food 3
... Doctors may soon be able to diagnose lung cancer ... Institute of Standards and Technology (NIST), where scientists have ... tomography (CT) scans and to lessen the amount of ... For years, radiologists have determined the size of ...
... Bacteria in the ocean can harvest light energy from ... novel finding by a team of scientists in Sweden and ... open access journal PLoS Biology . "It was ... sea that could harvest the energy from sunlight for growth," ...
... Baltimore, MDDouglas E. Koshland, staff scientist at Carnegie,s ... members of the National Academy of Sciences (NAS) for ... NAS is one of the highest honors given to ... will be inducted into the academy next April during ...
Cached Biology News:To improve lung cancer diagnosis, good medicine is a polymer pill 2Rhodopsin phototrophy promotes bacterial survival 2Carnegie's Doug Koshland elected to National Academy of Sciences 2
... coli containing a clone of the human Topoisomerase ... II alters the topological state of nucleic acids ... transient break which generates a separate DNA helix ... DNA passage mechanism, the enzyme can relax negatively ...
RNase-Free DNase 50 l...
supplied with 10x reaction buffer...
... RNase H degrades, as an endoribonuclease, ... DNA hybrids of natural origin, e.g. ... synthetic complexes, e.g. poly(A) x poly(dT). ... and 3-OH termini. Nearly no activity ...
Biology Products: